To evaluate the effects of Yangxinshi tablet on heart failure of pulmonary heart disease. Methods: Sixty patients with pulmonary heart disease in the hospital were randomly divided into control group and Yangxinshi group, with 30 cases in each group. After 30 days treatment, the clinical symptoms, LVEF, hs-CRP, NT-proBNP, blood lipid level, blood pressure and adverse reactions of all patients were detected. Results: After treatment, 1) the total effective rate of improving clinical symptom in Yangxinshi group (90.0%) was significantly higher than that of the control group (66.7%), and the difference was statistically significant (P<0.05); 2) LVEF in Yangxinshi group (55±3.3)% was significantly higher than that of in control group (50±2.4)%, and the difference was statistically significant (P<0.05); 3) the hs-CRP in Yangxinshi group (1.09±0.22) mg/L was significantly lower than that of the control group (1.34±0.31) mg/L and the difference was statistically significant (P<0.05); 4) the NT-proBNP in Yangxinshi group (641±145) ng/L was significantly lower than that of the control group (923±122) ng/L (P<0.05); 5) the blood lipid level in Yangxinshi group (P<0.05); 6) the blood pressure in Yangxinshi group (125±9.6/85±3.4)mmHg was lower than that of the control group (130±6.6/83±7.5) mmHg, but the difference was not statistically significant (P>0.05); 7) the incidence of adverse reactions in Yangxinshi group (6.7%) was significantly lower than that of the control group (16.7%) (P<0.05). Conclusion: Yangxinshi tablet on heart failure of pulmonary heart disease can significantly improve clinical symptom and blood lipid level, enhance LVEF, reduce hs-CRP, NT-proBNP and incidence of adverse reactions, which has high safety and a guiding significance for clinic.